JACC in a Flash | Growing Evidence Surrounding Lp(a), Trends in CVD Mortality in US, More
Featured topics and Editors' Picks from all of ACC's JACC Journals.
New original research – part of a special JACC focus issue on lipids – adds to the growing body of evidence surrounding lipoprotein(a) (Lp[a]) and its contribution as an independent causal risk factor for cardiovascular disease and aortic stenosis.
Explore emerging insights into Lp(a), novel lipid therapies and more.
The intersectionality of cardiac amyloidosis, aging and frailty is the focus of a State-of-the-Art Review published in JACC: Advances.
While cardiovascular disease mortality declined overall from 1999 to 2023, rates increased during the COVID-19 pandemic and recovery across different categories of disease has been uneven, according to a recent JACC Data Report.
Welcoming a New Look for JACC – Grounded in Listening and Service
For decades, JACC has aimed to be more than a journal; it has been a trusted resource, a professional companion, and a window into the evolving science and practice of cardiovascular care.
As we continue this mission, our first year offered an opportunity to step back and listen. We heard from members, readers and contributors about what's working, what could be better and how the journal might evolve. That feedback has shaped what we share with you now: a redesign of JACC's visual identity, in print and online formats.
This is not a break from the past, nor a reinvention prompted by new leadership. It's an evolution – grounded in what has come before, shaped by what we've heard and aimed at serving more effectively.
Here's what's new:
- A modern, cleaner layout to enhance readability and accessibility
- A new logo featuring interlocking circles – symbolizing progress, connection and the strength of the JACC family
- An improved digital experience with clearer navigation, timely content highlights and article pages designed for greater impact
These changes are a step forward, but not a final destination. We will continue to listen, learn and improve. As always, our goal is to serve this community as well as we can.
Thank you for your continued engagement and trust.
With appreciation,
Harlan M. Krumholz, MD, FACC
Editor-in-Chief, JACC
Transformative Insights From NY Valves
Coinciding with the 2025 NY Valves meeting, newly published research across the JACC Journals captures the full spectrum of innovation in structural heart care. Spanning breakthrough device technologies to reimagined clinical strategies, these contributions reflect the dynamic evolution of the field and the forward momentum shaping contemporary practice.
In JACC, Isaac George, MD, and colleagues report one-year outcomes from a first-in-human trial of a polymer surgical mitral valve, demonstrating stable hemodynamics and early safety in a young, largely rheumatic population. In a companion Viewpoint, Marc Gillinov, MD, et al., say these findings suggest the time has come for a "three-party system" in heart valve selection, highlighting the need to move beyond the binary choice of bioprosthetic or mechanical valves that has defined the field for decades.
Also in JACC, Syed Zaid, MD, FACC, et al., summarize key takeaways from the Heart Valve Collaboratory's 2024 workshop on multivalvular disease, focusing on aortic stenosis and mitral regurgitation (MR). Together they outline clinical gaps and a research roadmap to guide the future of transcatheter and surgical strategies for patients with combined valvular disease.
In JACC: Heart Failure, Gilbert H.L. Tang, MD, MSc, MBA, FACC, et al., report results from the EXPANDed MitraClip studies, showing that even patients with advanced secondary MR outside COAPT eligibility derive meaningful benefit from transcatheter edge-to-edge-repair (TEER) – including MR reduction, fewer hospitalizations and better quality of life.
JACC: Cardiovascular Interventions includes a suite of structural heart studies, highlights of which include:
- Original research investigating real-world safety and efficacy of transcatheter tricuspid valve replacement with the EVOQUE TTVR system in patients with severed tricuspid regurgitation.
- Featured clinical research reporting on the first-in-human experience of using multidetector computed tomography and fluoroscopy to evaluate valve frame expansion and geometry in redo-TAVR.
- Results from the REPAIR trial evaluating and comparing outcomes of secondary mitral regurgitation phenotypes in patients undergoing mitral valve TEER.
- A research letter describing "a simplified and patient anatomy-specific deployment technique to improve commissural alignment after TAVR" with the Evolut FX system.
- An updated meta-analysis on Sentinel cerebral embolic protection during TAVR.
Access a complete list of papers.
Clinical Topics: Cardiovascular Care Team, COVID-19 Hub, Diabetes and Cardiometabolic Disease, Dyslipidemia, Geriatric Cardiology, Heart Failure and Cardiomyopathies, Valvular Heart Disease, Advanced Lipid Testing, Hypertriglyceridemia, Lipid Metabolism, Nonstatins
Keywords: Cardiology Magazine, ACC Publications, Risk Factors, Coronary Disease, Aortic Valve Stenosis, Atherosclerosis, Cholesterol, LDL, Frailty, Aged, Amyloidosis, Triglycerides, Lipoprotein(a), Cardiovascular Diseases, Cause of Death, COVID-19, Inflammation
